Treatment discontinuation and tolerability as a function of dose and titration of duloxetine in the treatment of major depressive disorder.

Harada, Eiji; Shirakawa, Osamu; Satoi, Yoichi; Marangell, Lauren B; Escobar, Rodrigo

Harada, Eiji; Shirakawa, Osamu; Satoi, Yoichi; Marangell, Lauren B; Escobar, Rodrigo.

Afiliación

Harada E; Eli Lilly Japan K.K., Medicines Development Unit Japan, Medical Science, Kobe, Japan.
Shirakawa O; Department of Neuropsychiatry, Kinki University Faculty of Medicine, Osakasayama, Japan.
Satoi Y; Eli Lilly Japan K.K., Medicines Development Unit Japan, Statistical Science, Kobe, Japan.
Marangell LB; The University of Texas Health Science Center School of Medicine, Houston, TX, USA.
Escobar R; Eli Lilly and Company, Neuroscience, Indianapolis, IN, USA.

Neuropsychiatr Dis Treat ; 12: 89-97, 2016.

Article en En | MEDLINE | ID: mdl-26811681

Palabras clave

antidepressant; dose; duloxetine; major depressive disorder; titration

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Neuropsychiatr Dis Treat Año: 2016 Tipo del documento: Article País de afiliación: Japón

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google